Phase 2 study of RO4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933

BACKGROUND Aberrant Notch activation confers a proliferative advantage to many human tumors, including melanoma. This phase 2 trial assessed the antitumor activity of RO4929097, a gamma‐secretase inhibitor of Notch signaling, with respect to the progression‐free and overall survival of patients with advanced melanoma. METHODS Chemotherapy‐naive patients with metastatic melanoma of cutaneous or unknown origin were treated orally with RO4929097 at a dose of 20 mg daily 3 consecutive days per week. A 2‐step accrual design was used with an interim analysis of the first 32 patients and with continuation of enrollment if 4 or more of the 32 patients responded. RESULTS Thirty‐six patients from 23 institutions were enrolled; 32 patients were evaluable. RO4929097 was well tolerated, and most toxicities were grade 1 or 2. The most common toxicities were nausea (53%), fatigue (41%), and anemia (22%). There was 1 confirmed partial response lasting 7 months, and there were 8 patients with stable disease lasting at least through week 12, with 1 of these continuing for 31 months. The 6‐month progression‐free survival rate was 9% (95% confidence interval [CI], 2%‐22%), and the 1‐year overall survival rate was 50% (95% CI, 32%‐66%). Peripheral blood T‐cell assays showed no significant inhibition of the production of interleukin‐2, a surrogate pharmacodynamic marker of Notch inhibition, and this suggested that the drug levels were insufficient to achieve Notch target inhibition. CONCLUSIONS RO4929097 showed minimal clinical activity against metastatic melanoma in this phase 2 trial, possibly because of inadequate exposure to therapeutic drug levels. Although Notch inhibition remains a compelling target in melanoma, the results do not support further investigation of RO4929097 with this dose and schedule. Cancer 2015;121:432–440. © 2014 American Cancer Society. This phase 2 trial investigates the safety and efficacy of RO4929097, a gamma‐secretase inhibitor of Notch signaling, in patients with advanced melanoma and no prior systemic chemotherapy. RO4929097 is well tolerated but shows minimal clinical activity against metastatic melanoma, possibly in part because of a lack of adequate exposure of the tumor to therapeutic drug levels.